Apyx Medical Corp美股招股说明书(2025-11-17版)

This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but isnot complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer Subject to completion, dated November [●], 2025 PRELIMINARY PROSPECTUS SUPPLEMENT(To Prospectus dated December 2, 2022) APYX MEDICAL CORPORATION [●] Shares of Common StockPre-Funded Warrants to Purchase [●] Shares of Common Stock We are offering [●] shares of our common stock, par value $0.001 per share (the “Common Stock”)and, in lieu of Common Stock, toinvestors that so choose, pre-funded warrants to purchase up to [ ● ] shares of our Common Stock in this offering, to certaininstitutional investors, pursuant to this prospectus supplement and the accompanying prospectus. The public offering price of ourcommon stock is $[●] per share. The purchase price of each pre-funded warrant will equal the price per share at which shares of ourcommon stock are being sold in this offering, minus $0.001, which will be the exercise price of each pre-funded warrant. Each pre- The shares of our common stock being offered have been registered pursuant to an effective shelf registration statement on Form S-3(File No. 333-268532), which was declared effective on December 2, 2022. Our common stock is listed and trades on the Nasdaq Global Select Market under the symbol “APYX.” The last sale price of ourshares of common stock on November [●], 2025 was $[●] per share. (1) Includes an underwriting discount equal to 6.0% of the gross proceeds of this offering. This does not include the reimbursement ofcertain expenses of the underwriter that we have agreed to pay. See “Underwriting” beginning on page S-13 of this prospectus We have granted the underwriter an option for a period of 45 days from the date of this prospectus supplement to purchase up to anadditional [●] shares of our common stock from us at the public offering price, less underwriting discounts and commissions. The underwriter expects to deliver the shares of common stock and/or pre-funded warrants to purchasers on or about November [●],2025. Investing in our securities involves a high degree of risk. Before making any investment decision, you should carefully reviewand consider all the information in this prospectus supplement, the accompanying prospectus and the documents incorporated thisprospectus supplement and the risk factors incorporated by reference into this prospectus supplement and theaccompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these shares ordetermined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is Lucid Capital Markets Prospectus Supplement dated November [●], 2025. TABLE OF CONTENTS PROSPECTUS You should rely only on the information incorporated by reference or provided in this prospectus supplement and the accompanyingprospectus. We have not authorized anyone to provide you with different information. If anyone provides you with different orinconsistent information, you should not rely on it. This prospectus supplement and the accompanying prospectus do not constitute anoffer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement and the accompanyingprospectus in any jurisdiction where it is unlawful to make such offer or solicitation. You should assume that the information containedin this prospectus supplement or the accompanying prospectus, or any document incorporated by reference in this prospectussupplement or the accompanying prospectus, is accurate only as of the date of those respective documents. Neither the delivery of this ABOUT THIS PROSPECTUS SUPPLEMENT A registration statement on Form S-3 (File No. 333-268532) utilizing a shelf registration process relating to the securities described inthis prospectus supplement was initially filed with the Securities and Exchange Commission, or the SEC, on November 22, 2022, and This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering ofsecurities. The second part is the accompanying prospectus, which provides more general information, some of which may not applyto this offering. The information included or incorporated by reference in this prospectus supplement also adds to, updates and changesinformation contained or incorporated by reference in the accompanying prospectus. It is also important for you to read and considerall information contained in this prospectus supplement and the accompanying prospectus, including the documents we have referredyou to in the section entitled “Where You Can Find More Information” below in this prospectus supplement. If information included orincorporated by reference in this prospectus supplement is inconsistent w